Research Article
Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy
Table 1
Baseline characteristics of head and neck cancer patients with radiation therapy and study population after propensity score matching.
| Variables | Study population | Study population after PSM | Nonuser () | User () | value | Nonuser ( | User () | value | | % | | % | | % | | % |
| Age (years) | | | | | | | | | | | <45 | 11561 | 31.40 | 172 | 21.10 | <0.0001 | 173 | 21.23 | 172 | 21.10 | 0.9989 | 45 to 54 | 12835 | 34.86 | 259 | 31.78 | | 257 | 31.53 | 259 | 31.78 | | 55 to 64 | 7341 | 19.94 | 208 | 25.52 | | 210 | 25.77 | 208 | 25.52 | | 65 to 74 | 3789 | 10.29 | 126 | 15.46 | | 123 | 15.09 | 126 | 15.46 | | ≥75 | 1297 | 3.52 | 50 | 6.14 | | 52 | 6.38 | 50 | 6.14 | | Mean ± SD | 50.77 | | 54.75 | | <0.0001 | 54.51 | | 54.75 | | 0.6823 | Gender | | | | | | | | | | | Men | 31434 | 85.37 | 717 | 87.98 | 0.0367 | 722 | 88.59 | 717 | 87.98 | 0.7002 | Women | 5389 | 14.63 | 98 | 12.02 | | 93 | 11.41 | 98 | 12.02 | | Comorbidity | | | | | | | | | | | Hypertension | 5623 | 15.27 | 248 | 30.43 | <0.0001 | 257 | 31.53 | 248 | 30.43 | 0.6298 | Diabetes mellitus | 3399 | 9.23 | 178 | 21.84 | <0.0001 | 183 | 22.45 | 178 | 21.84 | 0.7655 | Dyslipidemia | 1828 | 4.96 | 72 | 8.83 | <0.0001 | 64 | 7.85 | 72 | 8.83 | 0.4737 | Chronic kidney disease | 279 | 0.76 | 23 | 2.82 | <0.0001 | 23 | 2.82 | 23 | 2.82 | 1.0000 | Heart failure | 314 | 0.85 | 38 | 4.66 | <0.0001 | 34 | 4.17 | 38 | 4.66 | 0.6297 | Atrial fibrillation | 162 | 0.44 | 16 | 1.96 | <0.0001 | 13 | 1.60 | 16 | 1.96 | 0.5740 | Gastrointestinal ulcer | 2968 | 8.06 | 70 | 8.59 | 0.5836 | 76 | 9.33 | 70 | 8.59 | 0.6028 | Ischemic heart disease | 1233 | 3.35 | 139 | 17.06 | <0.0001 | 137 | 16.81 | 139 | 17.06 | 0.8949 | Peripheral vascular disease | 87 | 0.24 | 8 | 0.98 | <0.0001 | 6 | 0.74 | 8 | 0.98 | 0.5914 | Deep venous thrombosis | 41 | 0.11 | 11 | 1.35 | <0.0001 | 9 | 1.10 | 11 | 1.35 | 0.6527 | Prescribed drug | | | | | | | | | | | ACEI | 550 | 1.49 | 55 | 6.75 | <0.0001 | 51 | 6.26 | 55 | 6.75 | 0.6878 | ARB | 274 | 0.74 | 30 | 3.68 | <0.0001 | 37 | 4.54 | 30 | 3.68 | 0.3825 | Beta blocker | 118 | 0.32 | 8 | 0.98 | 0.0012 | 8 | 0.98 | 8 | 0.98 | 1.0000 | CCB | 51 | 0.14 | 13 | 1.60 | <0.0001 | 15 | 1.84 | 13 | 1.60 | 0.7030 | NSAIDs | 13898 | 37.74 | 402 | 49.33 | <0.0001 | 415 | 50.92 | 402 | 49.33 | 0.5196 | PPI | 1335 | 3.63 | 82 | 10.06 | <0.0001 | 83 | 10.18 | 82 | 10.06 | 0.9346 | Statin | 84 | 0.23 | 13 | 1.60 | <0.0001 | 10 | 1.23 | 13 | 1.60 | 0.5287 |
|
|
PSM, propensity score matching; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor.
|